Pfizer announced the launch of 3 new biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab-qyyp).
Zirabev, a biosimilar to Avastin (bevacizumab; Genentech), is available for the treatment of 5 types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer. The product is supplied in single-dose vials in 100mg/4mL and 400mg/16mL strengths. The Wholesale Acquisition Cost (WAC) is $613.40 per 100mg single-dose vial and $2453.60 per 400mg single-dose vial.
Ruxience, a biosimilar to Rituxan (rituximab; Genentech and Biogen), is available for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis (GPA) and microscopic polyangitis (MPA). The product is supplied in single-dose vials as a 100mg/10mL and 500mg/50mL solution for intravenous infusion. The WAC is $716.80 per 100mg single-dose vial and $3584 per 500mg single-dose vial.
Trazimera, a biosimilar to Herceptin (trastuzumab; Genentech), will be made available on February 15, 2020 for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product will be supplied as 420mg lyophilized powder in a multi-dose vial for reconstitution. The WAC will be $3391.08 per 420mg multi-dose vial.
“We’re proud to expand our leading biosimilars portfolio by launching these 3 treatments, which can potentially create significant savings for the US healthcare system while increasing access to critical therapies,” said Angela Lukin, Regional President, North America Oncology at Pfizer. “We look forward to working with payers and providers to deliver these important medicines to patients that are living with certain cancers and autoimmune conditions.”
A biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.
For more information visit pfizer.com.